(SGMT)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Sagimet Biosciences Inc. klinik bosqichdagi biotexnologiya kompaniyasi bo'lib, Qo'shma Shtatlarda disfunksiyali metabolik va fibrotik yo'llar natijasida yuzaga keladigan kasalliklarni davolash uchun yog' kislotasi sintez (FASN) inhibitörleri deb nomlangan yangi terapevtik vositalarni ishlab chiqadi. Kompaniyaning asosiy dori nomzodi Denifanstat bo'lib, u og'iz orqali, kuniga bir marta qabul qilinadigan tabletka va metabolik disfunksiyaga bog'liq steatohepatit, akne va saratonning ayrim turlarini davolash uchun tanlangan FASN inhibitörüsidir. Shuningdek, u akne ko'rsatmasini davolash uchun FASN inhibitörüsü bo'lgan TVB-3567; va qattiq o'smalar va glial o'smalar kabi boshqa onkologik dasturlarni ishlab chiqadi. Kompaniya ilgari 3-V Biosciences, Inc. nomi bilan tanilgan va 2019-yil avgust oyida Sagimet Biosciences Inc. nomiga o'zgartirilgan. Sagimet Biosciences Inc. 2006-yilda ro'yxatga olingan va shtab-kvartirasi San-Mateo, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. | Chief Medical Officer |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder |
| Dr. Marie O'Farrell Ph.D. | Chief Scientific Officer |
| Mr. David A. Happel | CEO, President & Director |
| Mr. Robert D'Urso | Senior Vice President of New Products |
| Mr. Thierry Chauche | CFO & Principal Accounting Officer |
| Mr. Urs Greber Ph.D. | Co-Founder |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-11 | S-8 | tm268373d2_s8.htm |
| 2026-02-02 | 8-K | tm264534d1_8k.htm |
| 2025-12-18 | 8-K | tm2533462d2_8k.htm |
| 2025-12-17 | 8-K | tm2533462d1_8k.htm |
| 2025-11-13 | 10-Q | sgmt-20250930x10q.htm |
| 2025-10-23 | 8-K | tm2529317d1_8k.htm |
| 2025-08-22 | 8-K | tm2524100d1_8k.htm |
| 2025-08-13 | 10-Q | sgmt-20250630x10q.htm |
| 2025-06-10 | 8-K | tm2517631d1_8k.htm |
| 2025-06-04 | 8-K | tm2517101d1_8k.htm |
| Ms. Elizabeth Rozek Esq., J.D. |
| Chief Legal & Administrative Officer |